HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Conde, K. Articles by Fernandez, M. L. Search for Related Content PubMed PubMed Citation Articles by Conde, K. Articles by Fernandez, M. L. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 37, 2372-2382, Copyright © 1996 by Lipid Research, Inc.

ARTICLES

Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig

K Conde, M Vergara-Jimenez, BR Krause, RS Newton and ML Fernandez
Department of Nutritional Sciences, University of Arizona, Tucson 85721, USA.

Guinea pigs were fed 15% (w/W) fat, high in lauric and myristic acids, a diet known to produce hypercholesterolemia in these animals. The diet was given alone or in combination with four doses of atorvastatin equivalent to 1, 3, 10, and 20 mg/kg per day. Atorvastatin reduced plasma LDL cholesterol concentrations by 46, 50, 53, and 70%, respectively (P < 0.001). Plasma apoB concentrations were reduced by atorvastatin (P < 0.001) and compositional changes occurred in VLDL and LDL with reductions of the relative proportion of cholesteryl ester and increases in triacylglycerol. A reduction in hepatic cholesteryl ester (66%) was observed only with the highest atorvastatin dose (20 mg/kg per day) while microsomal cholesterol was reduced by 30% with 3-20 mg/kg per day. Hepatic ACAT activity was down-regulated and apoB/E receptor number was increased by atorvastatin. In contrast, HMG-CoA reductase activity and cholesterol 7 alpha-hydroxylase were not affected by the drug. VLDL apoB secretion rates were decreased by atorvastatin treatment 59 and 76% with 3 and 20 mg/kg per day, respectively. Nascent VLDL particles were larger after drug treatment, showing an increased number in triacylglycerol molecules. These results support the hypothesis that the plasma LDL lowering induced by atorvastatin is due to a decreased secretion of apoB in combination with an increase of hepatic apoB/E receptors.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. H. Samson The Role of Statin Drugs in the Management of the Peripheral Vascular Patient Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366. [Abstract] [PDF]

				M. Torres-Gonzalez, S. Shrestha, M. Sharman, H. C. Freake, J. S. Volek, and M. L. Fernandez Carbohydrate Restriction Alters Hepatic Cholesterol Metabolism in Guinea Pigs Fed a Hypercholesterolemic Diet J. Nutr., October 1, 2007; 137(10): 2219 - 2223. [Abstract] [Full Text] [PDF]

				K. L. West, T. Ramjiganesh, S. Roy, B. T. Keller, and M. L. Fernandez 1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane Methanesulfonate (SC-435), an Ileal Apical Sodium-Codependent Bile Acid Transporter Inhibitor Alters Hepatic Cholesterol Metabolism and Lowers Plasma Low-Density Lipoprotein-Cholesterol Concentrations in Guinea Pigs J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 293 - 299. [Abstract] [Full Text] [PDF]

				M. L. Fernandez Guinea Pigs as Models for Cholesterol and Lipoprotein Metabolism J. Nutr., January 1, 2001; 131(1): 10 - 20. [Abstract] [Full Text]

				S. Roy, S. Vega-Lopez, and M. L. Fernandez Gender and Hormonal Status Affect the Hypolipidemic Mechanisms of Dietary Soluble Fiber in Guinea Pigs J. Nutr., March 1, 2000; 130(3): 600 - 607. [Abstract] [Full Text]

				G. J. Schroepfer Jr. Oxysterols: Modulators of Cholesterol Metabolism and Other Processes Physiol Rev, January 1, 2000; 80(1): 361 - 554. [Abstract] [Full Text] [PDF]

				J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs Endocrinology, November 1, 1999; 140(11): 5293 - 5302. [Abstract] [Full Text]

				L. J. Wilcox, P. H. R. Barrett, and M. W. Huff Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin J. Lipid Res., June 1, 1999; 40(6): 1078 - 1089. [Abstract] [Full Text]

				R. G. Elkin, Z. Yan, Y. Zhong, S. S. Donkin, K. K. Buhman, J. A. Story, J. J. Turek, R. E. Porter Jr., M. Anderson, R. Homan, et al. Select 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Vary in Their Ability to Reduce Egg Yolk Cholesterol Levels in Laying Hens through Alteration of Hepatic Cholesterol Biosynthesis and Plasma VLDL Composition J. Nutr., May 1, 1999; 129(5): 1010 - 1019. [Abstract] [Full Text]

				A. Mohammadi, J. Macri, R. Newton, T. Romain, D. Dulay, and K. Adeli Effects of Atorvastatin on the Intracellular Stability and Secretion of Apolipoprotein B in HepG2 Cells Arterioscler. Thromb. Vasc. Biol., May 1, 1998; 18(5): 783 - 793. [Abstract] [Full Text] [PDF]

				G. C. Ness, C. M. Chambers, and D. Lopez Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity J. Lipid Res., January 1, 1998; 39(1): 75 - 84. [Abstract] [Full Text]

				J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2589 - 2600. [Abstract] [Full Text]